var data={"title":"Fomepizole: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Fomepizole: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6231?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=fomepizole-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Fomepizole: Pediatric drug information&quot;</a> and <a href=\"topic.htm?path=fomepizole-patient-drug-information\" class=\"drug drug_patient\">see &quot;Fomepizole: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173900\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Antizol</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15125571\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Antizol</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173919\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antidote</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173901\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Fomepizole therapy should begin immediately upon suspicion of ethylene glycol or methanol ingestion.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Ethylene glycol and methanol toxicity:</b> IV: Loading dose of 15 mg/kg should be administered, followed by doses of 10 mg/kg every 12 hours for 4 doses, then 15 mg/kg every 12 hours thereafter until ethylene glycol or methanol concentrations have been reduced to &lt;20 mg/dL and patient is asymptomatic with normal pH. <b>Note:</b> For severe toxicity requiring concomitant hemodialysis, see dosage adjustment in renal impairment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173911\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=fomepizole-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Fomepizole: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Ethylene glycol and methanol toxicity (off-label use):</b> Safe and efficacious use in this patient population for ethylene glycol and methanol intoxication has been reported (Baum 2000; Benitez 2000; Boyer 2001; Brown 2001; De Brabander 2005; Detaille 2004; Fisher 1998). Consider consultation with a clinical toxicologist or poison control center. Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173902\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Specific studies have not been conducted in elderly patients.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173903\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;margin-left:0em;margin-top:0em;text-align:justify;display:inline\"> <b>Note:</b> Hemodialysis should be considered as an adjunct to fomepizole in patients with renal failure, significant or worsening metabolic acidosis, or ethylene glycol or methanol concentrations &ge;50 mg/dL. The following dosing adjustments should be used for any patient receiving hemodialysis regardless of renal function.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Prior to the start of hemodialysis: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">To determine if the patient requires a dose of fomepizole at the start of hemodialysis, determine when the last dose was administered.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">If the last dose of fomepizole was given &lt;6 hours ago, do not administer another dose upon beginning hemodialysis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">If the last dose of fomepizole was given &ge;6 hours ago, administer next scheduled dose upon beginning hemodialysis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>During hemodialysis: </b> During hemodialysis, administer fomepizole every 4 hours. Alternatively, a loading dose of 10-20 mg/kg followed by 1-1.5 mg/kg/hour continuous infusion during hemodialysis has been described in case reports (Jobard, 1996).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Upon completion of hemodialysis:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">To determine if the patient requires a dose of fomepizole at the time of completion of hemodialysis, determine when the last dose was administered. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">If the last dose of fomepizole was given &lt;1 hour ago, do not administer a dose at the end of hemodialysis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">If the last dose of fomepizole was given 1-3 hours ago, administer one-half of the next scheduled dose at the end of hemodialysis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">If the last dose of fomepizole was given &gt;3 hours ago, administer the next scheduled dose at the end of hemodialysis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Maintenance dose when off hemodialysis:</b> Administer fomepizole every 12 hours (starting 12 hours from last dose administered).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173904\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">Fomepizole is metabolized in the liver. Specific dosage adjustments have not been determined in patients with hepatic impairment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173877\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Antizol: 1 g/mL (1.5 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 g/mL (1.5 mL); 1.5 g/1.5 mL (1.5 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173863\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173880\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV: All doses should be administered as a slow intravenous infusion (IVPB) over 30 minutes.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173879\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Ethylene glycol or methanol poisoning:</b> Treatment of methanol or ethylene glycol poisoning alone or in combination with hemodialysis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <b>Note:</b> Fomepizole is the preferred antidote for known or suspected ethylene glycol poisoning or methanol poisoning. If fomepizole is unavailable or if the patient is intolerant to fomepizole, ethanol therapy may be considered. Ethanol as an antidote is effective in the management of methanol and ethylene glycol poisoning (Thanacoody 2016; Zakharov 2015); however, ethanol is associated with a higher incidence of adverse events and medication errors (Bestic 2009; Lepik 2009; Lepik 2011).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7914140\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Fomepizole may be confused with omeprazole</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173870\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (14%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10% (&le;3% unless otherwise noted):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Bradycardia, facial flushing, hypotension, phlebitis, shock, tachycardia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Dizziness (6%), drowsiness (6%), metallic taste (&le;6%), agitation, altered sense of smell, anxiety, seizure, speech disturbance, vertigo</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Unpleasant taste (&le;6%), abdominal pain, decreased appetite, diarrhea, heartburn, hiccups, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Anuria</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Anemia, disseminated intravascular coagulation (DIC), eosinophilia, lymphangitis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased liver enzymes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Application site reaction, inflammation at injection site, pain at injection site</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Back pain</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Nystagmus, transient blurred vision, visual disturbance</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Pharyngitis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever, multi-organ failure</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing and/or case reports: Hypersensitivity reaction (mild; mild rash, eosinophilia)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173883\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to fomepizole, other pyrazoles, or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173867\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment; metabolized in the liver.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use with caution in patients with renal impairment; fomepizole and its metabolites are excreted in the urine. Hemodialysis should be considered as an adjunct to fomepizole in patients with renal failure, significant acidosis (pH &lt;7.25-7.3), worsening metabolic acidosis, or ethylene glycol or methanol concentrations &ge;50 mg/dL.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Pediatric: Pediatric administration is not FDA approved; however, safe and efficacious use in this patient population for ethylene glycol and methanol intoxication has been reported (Baum, 2000; Benitez, 2000; Boyer, 2001; Brown, 2001; De Brabander, 2005; Detaille, 2004; Fisher, 1998).  Consider consultation with a clinical toxicologist or poison control center. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Administration: Should not be given undiluted or by bolus injection. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299362\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6220494\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8633&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:0em;display:inline\">There are no known significant interactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173897\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Ethanol decreases the rate of fomepizole elimination by ~50%; conversely, fomepizole decreases the rate of elimination of ethanol by ~40%.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173873\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173886\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. In general, medications used as antidotes should take into consideration the health and prognosis of the mother; antidotes should be administered to pregnant women if there is a clear indication for use and should not be withheld because of fears of teratogenicity (Bailey, 2003).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16355483\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if fomepizole is excreted in breast milk. The manufacturer recommends that caution be exercised when administering fomepizole to nursing women. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173875\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ideally, fomepizole plasma concentrations should be monitored; however, fomepizole concentrations are generally not available.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Use these parameters to monitor the response to fomepizole: Plasma (preferred)/urinary ethylene glycol or methanol concentrations, urinary oxalate (ethylene glycol), plasma (preferred)/urinary osmolality, renal/hepatic function, serum electrolytes, arterial blood gases; anion and osmolar gaps, resolution of clinical signs and symptoms of ethylene glycol or methanol intoxication</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173878\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">The manufacturer recommends concentrations 100 to 300 micromole/L (8.2 to 24.6 mg/L) to achieve enzyme inhibition of alcohol dehydrogenase; according to practice guidelines, serum fomepizole concentrations of &ge;0.8 mg/L provide constant inhibition of alcohol dehydrogenase (Barceloux 1999; Barceloux 2002). However, fomepizole concentrations are generally not available.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173866\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Fomepizole competitively inhibits alcohol dehydrogenase, an enzyme which catalyzes the metabolism of ethanol, ethylene glycol, and methanol to their toxic metabolites. Ethylene glycol is metabolized to glycoaldehyde, then oxidized to glycolate, glyoxylate, and oxalate. Glycolate and oxalate are responsible for metabolic acidosis and renal damage. Methanol is metabolized to formaldehyde, then oxidized to formic acid. Formic acid is responsible for metabolic acidosis and visual disturbances.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173882\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of effect: Peak effect: Maximum: 1.5-2 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Oral: Readily absorbed </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: 0.6-1.02 L/kg; rapidly into total body water </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: Negligible </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic to 4-carboxypyrazole (80% to 85% of dose), 4-hydroxymethylpyrazole, and their N-glucuronide conjugates; following multiple doses, induces its own metabolism via CYP oxidases after 30-40 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Has not been calculated; varies with dose </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (1% to 3.5% as unchanged drug and metabolites)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323159\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Antizol Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g/mL (1.5 mL): $1,849.80</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Fomepizole Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g/mL (1.5 mL): $1,290.00</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038622\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Antizol (GB, IE);</li>\n      <li>FomepizoleAP-HP (FR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Antizol (fomepizole) [product monograph]. St-Laurent, Quebec, Canada: Paladin Labs Inc; October 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bailey B, &quot;Are There Teratogenic Risks Associated With Antidotes Used in the Acute Management of Poisoned Pregnant Women?&quot; <i>Birth Defects Res A Clin Mol Teratol</i>, 2003, 67(2):133-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fomepizole-drug-information/abstract-text/12769509/pubmed\" target=\"_blank\" id=\"12769509\">12769509</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Barceloux DG, Bond GR, Krenzelok EP, et al, &ldquo;American Academy of Clinical Toxicology Practice Guidelines on the Treatment of Methanol Poisoning,&rdquo; <i>J Toxicol Clin Toxicol</i>, 2002, 40(4):415-46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fomepizole-drug-information/abstract-text/12216995/pubmed\" target=\"_blank\" id=\"12216995\">12216995</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Barceloux DG, Krenzelok EP, Olson K, et al, &quot;American Academy of Clinical Toxicology Practice Guidelines on the Treatment of Ethylene Glycol Poisoning. Ad Hoc Committee,&quot; <i>J Toxicol Clin Toxicol</i>, 1999, 37(5):537-60.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fomepizole-drug-information/abstract-text/10497633/pubmed\" target=\"_blank\" id=\"10497633\">10497633</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Battistella M, &ldquo;Fomepizole as an Antidote for Ethylene Glycol Poisoning,&rdquo; <i>Ann Pharmacother</i>, 2002, 36(6):1085-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fomepizole-drug-information/abstract-text/12022913/pubmed\" target=\"_blank\" id=\"12022913\">12022913</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baum CR, Langman CB, Oker EE, et al, &ldquo;Fomepizole Treatment of Ethylene Glycol Poisoning in an Infant,&rdquo; <i>Pediatrics</i>, 2000, 106(6):1489-91.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fomepizole-drug-information/abstract-text/11099610/pubmed\" target=\"_blank\" id=\"11099610\">11099610</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Benitez JG, Swanson-Biearman B, and Krenzelok EP, &ldquo;Nystagmus Secondary to Fomepizole Administration in a Pediatric Patient,&rdquo; <i>J Toxicol Clin Toxicol</i>, 2000, 38(7):795-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fomepizole-drug-information/abstract-text/11192468/pubmed\" target=\"_blank\" id=\"11192468\">11192468</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bestic M, Blackford M, Reed M. Fomepizole: a critical assessment of current dosing recommendations. <i>J Clin Pharmacol</i>. 2009;49(2):130-137.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fomepizole-drug-information/abstract-text/19004845/pubmed\" target=\"_blank\" id=\"19004845\">19004845</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Borron SW and Baud FJ, &ldquo;Intravenous 4-Methylpyrazole as an Antidote for Diethylene Glycol and Triethylene Glycol Poisoning: A Case Report,&rdquo; <i>Vet Hum Toxicol</i>, 1997, 37(1):26-8.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Boyer EW, Mejia M, Woolf A, et al, &ldquo;Severe Ethylene Glycol Ingestion Treated Without Hemodialysis,&rdquo; <i>Pediatrics</i>, 2001, 107(1):172-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fomepizole-drug-information/abstract-text/11134452/pubmed\" target=\"_blank\" id=\"11134452\">11134452</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brent J. Fomepizole for the treatment of pediatric ethylene and diethylene glycol, butoxyethanol, and methanol poisonings. <i>Clin Toxicol (Phila)</i>. 2010;48(5):401-406.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fomepizole-drug-information/abstract-text/20586570/pubmed\" target=\"_blank\" id=\"20586570\">20586570</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brent J, McMartin K, Phillips S, et al, &ldquo;4-Methylpyrazole (Fomepizole) Therapy of Ethylene Glycol Poisoning: Preliminary Results of the Meta Trial,&rdquo; <i>J Toxicol Clin Toxicol</i>, 1997, 35(5):507.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brent J, McMartin K, Phillips S, et al, &ldquo;4-Methylpyrazole (Fomepizole) Therapy of Methanol Poisoning: Preliminary Results of the Meta Trial,&rdquo; <i>J Toxicol Clin Toxicol</i>, 1997, 35(5):507.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brent J, McMartin K, Phillips S, et al, &ldquo;Fomepizole for the Treatment of Methanol Poisoning,&rdquo; <i>N Engl J Med</i>, 2001, 344(6):424-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fomepizole-drug-information/abstract-text/11172179/pubmed\" target=\"_blank\" id=\"11172179\">11172179</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brown MJ, Shannon MW, Woolf A, et al, &ldquo;Childhood Methanol Ingestion Treated With Fomepizole and Hemodialysis,&rdquo; <i>Pediatrics</i>, 2001, 108(4):e77-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fomepizole-drug-information/abstract-text/11581485/pubmed\" target=\"_blank\" id=\"11581485\">11581485</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    De Brabander N, Wojciechowski M, De Decker K, et al, &ldquo;Fomepizole as a Therapeutic Strategy in Paediatric Methanol Poisoning: A Case Report and Review of the Literature,&rdquo; <i>Eur J Pediatr</i>, 2005, 164(3):158-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fomepizole-drug-information/abstract-text/15578220/pubmed\" target=\"_blank\" id=\"15578220\">15578220</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Detaille T, Wallemacq P, Clement de Clety S, et al, &ldquo;Fomepizole Alone for Severe Infant Ethylene Glycol Poisoning,&rdquo; <i>Pediatr Crit Care Med</i>, 2004, 5(5):490-1.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fomepizole-drug-information/abstract-text/15329167/pubmed\" target=\"_blank\" id=\"15329167\">15329167</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fisher DM and Diaz JE, &ldquo;Pediatric Methanol Poisoning Treated With Fomepizole (Antizol&reg;),&rdquo; <i>J Toxicol Clin Toxicol</i>, 1998, 36:512.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hung O, Kaplan J, Hoffman R, et al, &ldquo;Improved Understanding of the Ethanol-Chloral Hydrate Interaction Using 4-MP,&rdquo; <i>J Toxicol Clin Toxicol</i>, 1997, 35(5):507-8.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jacobsen D and McMartin KE, &ldquo;4-Methylpyrazole - Present Status,&rdquo; <i>J Toxicol Clin Toxicol</i>, 1996, 34(4):379-81.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fomepizole-drug-information/abstract-text/8699551/pubmed\" target=\"_blank\" id=\"8699551\">8699551</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jacobsen D and McMartin KE, &ldquo;Antidotes for Methanol and Ethylene Glycol Poisoning,&rdquo; <i>J Toxicol Clin Toxicol</i>, 1997, 35(2):127-43.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fomepizole-drug-information/abstract-text/9120880/pubmed\" target=\"_blank\" id=\"9120880\">9120880</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jacobsen D, Ostensen J, Bredesen L, et al, &ldquo;4-Methylpyrazole (4-MP) Is Effectively Removed by Haemodialysis in the Pig Model,&rdquo; <i>Hum Exp Toxicol</i>, 1996, 15(6):494-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fomepizole-drug-information/abstract-text/8793532/pubmed\" target=\"_blank\" id=\"8793532\">8793532</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jacobsen D, Sebastian CS, Barron SK, et al, &ldquo;Effects of 4-Methylpyrazole, Methanol/Ethylene Glycol Antidote in Healthy Humans,&rdquo; <i>J Emerg Med</i>, 1990, 8(4):455-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fomepizole-drug-information/abstract-text/2212566/pubmed\" target=\"_blank\" id=\"2212566\">2212566</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jobard E, Harry P, Turcant A, et al, &ldquo;4-Methylpyrazole and Hemodialysis in Ethylene Glycol Poisoning,&rdquo; <i>J Toxicol Clin Toxicol</i>, 1996, 34(4):373-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fomepizole-drug-information/abstract-text/8699550/pubmed\" target=\"_blank\" id=\"8699550\">8699550</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lepik KJ, Levy AR, Sobolev BG, et al. Adverse drug events associated with the antidotes for methanol and ethylene glycol poisoning: a comparison of ethanol and fomepizole. <i>Ann Emerg Med</i>. 2009;53(4):439-450.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fomepizole-drug-information/abstract-text/18639955/pubmed\" target=\"_blank\" id=\"18639955\">18639955</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lepik KJ, Sobolev BG, Levy AR, et al. Medication errors associated with the use of ethanol and fomepizole as antidotes for methanol and ethylene glycol poisoning. <i>Clin Toxicol (Phila)</i>. 2011;49(5):391-401.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fomepizole-drug-information/abstract-text/21740138/pubmed\" target=\"_blank\" id=\"21740138\">21740138</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McMartin K, Jacobsen D, Hovda KE. Antidotes for poisoning by alcohols that form toxic metabolites. <i>Br J Clin Pharmacol</i>. 2016;81(3):505-515.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fomepizole-drug-information/abstract-text/26551875/pubmed\" target=\"_blank\" id=\"26551875\">26551875</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McMartin KE and Heath A, &ldquo;Treatment of Ethylene Glycol Poisoning With Intravenous 4-Methylpyrazole,&rdquo; <i>N Engl J Med</i>, 1989, 320(2):125.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mokhlesi B, Leikin JB, Murray P, et al, &ldquo;Adult Toxicology in Critical Care: Part II: Specific Poisonings,&rdquo; <i>Chest</i>, 2003, 123(3):897-922.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fomepizole-drug-information/abstract-text/12628894/pubmed\" target=\"_blank\" id=\"12628894\">12628894</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Roberts DM, Yates C, Megarbane B, et al. Recommendations for the role of extracorporeal treatments in the management of acute methanol poisoning: a systematic review and consensus statement. <i>Crit Care Med</i>. 2015;43(2):461-472.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fomepizole-drug-information/abstract-text/25493973/pubmed\" target=\"_blank\" id=\"25493973\">25493973</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Thanacoody RH, Gilfillan C, Bradberry SM, et al. Management of poisoning with ethylene glycol and methanol in the UK: a prospective study conducted by the National Poisons Information Service (NPIS). <i>Clin Toxicol (Phila)</i>. 2016;54(2):134-140.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fomepizole-drug-information/abstract-text/26594941/pubmed\" target=\"_blank\" id=\"26594941\">26594941</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zakharov S, Pelclova D, Navratil T, et al. Fomepizole versus ethanol in the treatment of acute methanol poisoning: Comparison of clinical effectiveness in a mass poisoning outbreak. <i>Clin Toxicol (Phila)</i>. 2015;53(8):797-806.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fomepizole-drug-information/abstract-text/26109326/pubmed\" target=\"_blank\" id=\"26109326\">26109326</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8633 Version 91.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F173900\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F15125571\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F173919\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F173901\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F173911\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F173902\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F173903\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F173904\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F173877\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F173863\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F173880\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F173879\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F7914140\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F173870\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F173883\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F173867\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299362\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6220494\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F173897\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F173873\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F173886\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F16355483\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F173875\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F173878\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F173866\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F173882\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323159\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038622\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8633|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=fomepizole-patient-drug-information\" class=\"drug drug_patient\">Fomepizole: Patient drug information</a></li><li><a href=\"topic.htm?path=fomepizole-pediatric-drug-information\" class=\"drug drug_pediatric\">Fomepizole: Pediatric drug information</a></li></ul></div></div>","javascript":null}